Aristotle University Of Thessaloniki (AUTH)
Συγκριτική μορφολογική, ανοσοϊστοχημική και μοριακή μελέτη καρκινωμάτων μαστού με τη μέθοδο των μικροσυστοιχιών
Abstract
dc:descriptionSince, target therapy against HER2 and EGFR has been developed and used in some malignancies in addition with under development therapeutic agents that inhibit autophosphorylation sites we aim to find out how often breast carcinomas overexpress HER2 and EGFR and what the role of HST is. Herstatin (HST) is a truncated protein produced by alternative splicing from the HER2 gene. In experimental systems, HST has been reported to act as an endogenous pan-HER inhibitor by disrupting HER dimers in way similar to that of manufactured monoclonal antibodies with putative therapeutic use, e.g., pertuzumab. However, the role of HST, if any, in adult human tissues, remains unknown. With this scope, HST expression was assessed in the present study at the mRNA (real time PCR) and protein (immunohistochemistry [IHC]) level in parallel with parameters reflecting the activation status of HER2 in 187 breast carcinomas (BC) and matched non-cancerous breast (NCBT) tissues. All NCBTs and 93% of tumors expressed HST mRNA. NCBTs demonstrated the highest HST/HER2 transcript ratios that still corresponded to a few faintly positive epithelial and stromal cells by IHC. Although HST/HER2 transcript ratios in tumors were negatively associated with HER2 IHC grading, relative HST expression within the same tumor/NCBT system was almost constant. Positivity for HST protein was found in 46/187 (25%) of tumors but it was not predicted by the corresponding HST/HER2 ratio or relative HST expression. A subgroup of HER2 IHC-3+ tumors was identified exhibiting high HST/HER2 transcript ratios, strong HST protein positivity, as well as cytoplasmic phosphoAkt/PKB and p21CIP1/WAF1 protein localization. HST protein presence was associated with cytoplasmic localization of phosphoHER2-Y1248 (p=0.006) and non-membranous HER3 (p=0.003). There was no association with EGFR protein. There is a discrepancy between EGFRpharmDX and EGFR phosphorylated forms expression, suggesting that for targeted therapy the evaluation only of EGFRpharmDX might not be adequate. Moreover, the above findings do not support the view of HST as a tumor inhibitor and might be taken into account when designing clinical studies to test pan-HER antibodies in breast cancer.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koletsa, Triantafyllia
- Κολέτσα, Τριανταφυλλιά
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19454